Member exclusive

Academy Urges Insurers to Suspend Step Therapy Due to Potential Avastin Supply Issues

Oct 30, 2024

Administrative Burden

Step Therapy

Public Health & Safety

The Academy urged large commercial insurers and Medicare Advantage plans to suspend anti-VEGF step therapy requirements in response to Pine Pharmaceuticals discontinuation of repackaged Avastin (bevacizumab).

Member exclusive

Log in to keep reading.

Join AAO to get unlimited access to content. See member benefits or join today.